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Introduction: Sleep disturbances and pain are common non-motor symptoms in
Parkinson’s disease (PD). This study aimed to explore the association between these two
symptoms in a cohort of patients with PD.
Materials and methods: The Parkinson’s Disease Sleep Scale (PDSS-2) was used to
identify sleep disturbances in a series of 229 PD patients. The identification and character-
ization of pain was performed by a semi-structured interview and by the application of the
Ford classification and the Brief Pain Inventory (BPI). The Unified Parkinson’s Disease
Rating Scale-III, Hoehn & Yahr (H&Y), and Schwab and England Independence Scale were
used to assess motor symptoms and functional independence in off and on conditions. The
Hospital Anxiety and Depression Scale (HADS) and SF-36 were applied to screen for
anxiety and depression and to evaluate the quality of life. Non-parametric tests were used
for group comparisons and logistic regressions were applied to explore predictors of sleep
disturbances.
Results: Seventy-five (33%) patients had clinically relevant sleep disturbances (PDSS-2≥18)
and 162 patients (71%) reported pain. Of those with pain, 38 (24%) had central parkinsonian
pain. PD patients with sleep disturbances experienced more pain and had more severe motor
symptoms, lower functional independence, more anxiety and depression symptoms, and
worst quality of life. Among patients with pain, central parkinsonian pain was the subtype
of pain with the highest odds of sleep disturbances, even when taking into account motor
symptoms (H&Y off), motor fluctuations, intensity of pain (BPI), and symptoms of anxiety
and depression (HADS).
Conclusions: The association between pain and sleep disturbances in PD appears to be
dependent on subtype of pain. The close relationship between central parkinsonian pain and
sleep disturbances in PD raises the possibility of common pathophysiological mechanisms. A
better understanding of the relationship between sleep disturbances and central parkinsonian
pain may contribute to the development of new care strategies in PD patients.
Keywords: Parkinson’s disease, sleep disturbances, central parkinsonian pain
Introduction
Parkinson’s disease (PD) has been classically described as a disease with motor
symptoms, such as bradykinesia, tremor at rest, rigidity, and postural instability.1
Though PD is a complex disorder that also includes non-motor symptoms, such as
dementia, depression, sleep disorders, autonomic dysfunction, and sensory
symptoms.2 The co-occurrence of certain non-motor symptoms has raised the hypoth-
esis of clinical non-motor subtypes with specific pathophysiological patterns.3
Sleep disturbances are a common disabling non-motor symptom in PD, its
prevalence varies greatly from 40% to 90% in these patients, and may interfere
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with patients’ quality of life.4 The association between
poor sleep quality in PD and symptoms of depression
and anxiety has been well established.5 There is also
evidence that common sleep problems, such as sleep-
onset insomnia and sleep-maintenance insomnia, may be
associated with motor symptoms (eg, nocturnal akinesia)
and other non-motor symptoms (eg nocturia,
hallucinations).6,7
Pain is also a major and disabling non-motor symptom
in PD, with a prevalence of up to 85%.8 Pain is one of the
most bothersome non-motor symptoms and is known to be
associated with lower quality of life9 and more severe non-
motor symptoms.10
In general population, sleep disturbances and pain are
frequent co-morbidities. There is evidence from experi-
mental and longitudinal studies that pain and sleep inter-
act in a bidirectional manner and negatively affect each
other.11 In PD, studies have shown that sleep disturbances
are a risk factor for pain and vice versa.10,12–16
Pain in PD can be classified according to its clinical
features in five subtypes.17 One of the subtypes is central
parkinsonian pain, which is believed to be the only sub-
type of pain that is a direct consequence of the disease
itself, resulting from abnormal painful information proces-
sing, and not the result of dystonia, rigidity, or a muscu-
loskeletal cause, and is considered a neuropathic pain.17–20
The association between this subtype of pain with sleep
disturbances has yet to be investigated.
The general aims of this study were to identify in a
cohort of PD predictors of sleep disturbances and to
explore the relationship between sleep disturbances and
pain, according to pain features.
Materials and methods
Participants
A cross-sectional study of PD patients (diagnosis accord-
ing to the United Kingdom Brain Bank criteria)21 was
carried out in the Movement Disorders Clinic of Centro
Hospitalar Universitário do Porto. Exposition to drug-
induced parkinsonism, vascular parkinsonism, possible or
probable atypical parkinsonian syndromes, and advanced
therapies (subcutaneous apomorphine pump, levodopa-
carbidopa intestinal gel, or deep brain stimulation) were
considered a priori exclusion criteria. From a consecutive
series of 322 possible subjects (Figure 1), 229 participated
in the study. One patient refused to participate in the study.
Twenty-six were excluded before assessment (ie, seven
died, two developed other debilitating conditions, thirteen
moved geographically to a region not dependent from our
center or could not be reached between inclusion and
assessment, and four could not be assessed due to logistic
problems) and 66 were excluded after the assessment (ie,
one due to misdiagnosis and 65 due to incomplete
data set).
All the patients (or legal representatives) were
informed about the nature of the study and gave written
informed consent, in compliance with the Declaration of
Helsinki. The ethics committee of Centro Hospitalar e
Universitário do Porto approved the study.
Procedures
Based on an interview and clinical records, the following
data were collected: sex, age, age at PD onset, first motor
symptom, and current treatments. Current antiparkinsonian
322
consecutive
PD patients
93 excluded
1 refuses to
participate
26 excluded
before
assessment
66 excluded
after
assessment
154 with
PDSS-2<18
75 with
PDSS-2≥18
101 with
pain
53 without
pain
14 without
pain 61 with pain
229 included
Figure 1 Flowchart of the study sample.
Abbreviation: PDSS-2, Parkinson's Disease Sleep Scale.
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medication was converted to levodopa equivalent dose.22
A movement disorders specialist performed a neurological
examination to all participants. Thirty patients (12%) were
evaluated at home due to the severity of their motor
symptoms. PD patients were evaluated in the morning
without antiparkinsonian medication for 12 hrs (off med-
ication condition), using the Unified Parkinson’s Disease
Rating Scale (UPDRS)23 and the modified Hoehn & Yahr
Scale (H&Y).24 Presence of motor fluctuations was iden-
tified by UPDRS-IV items 36, 37, and 38. After the assess-
ment in off, patients took their usual first dose of
antiparkinsonian medication and were re-evaluated 1 hr
later (on medication condition), using the same instru-
ments. Then, the Schwab and England Independence
Scale (S&E) was applied regarding their state on and off.25
The Parkinson`s Disease Sleep Scale (PDSS-2) was
used to screen for sleep disturbances.26 The applied cutoff
score for clinically relevant sleep disturbances was
PDSS-2≥18.27
All patients were tasked whether they had pain in the
last month. Those who responded “yes” to the previous
question were asked a series of questions regarding their
pain: onset; duration; localization; features (including
burning, tingling, formication, stabbing, aching, tension,
tightness, or radiating); intensity; frequency; precipitating/
relieving factors; temporal and topographical relationship
with PD symptoms; and influence of motor complications,
dyskinesias, and dopaminergic medication. Based on the
patients’ description, the neurologist categorized the pain,
according to Ford framework,17 as central parkinsonian
pain, musculoskeletal pain, dystonia-related pain, radicular
or neuropathic pain, and akathitic discomfort. Central par-
kinsonian pain was defined, according to Ford criteria,17 as
burning, tingling, formication, or “neuropathic” sensa-
tions, often relentless and bizarre in quality, not confined
to root or nerve territory, and not explained by rigidity,
dystonia, musculoskeletal, or internal lesion. The Brief
Pain Inventory (BPI) was applied.28
The Hospital Anxiety and Depression Scale (HADS)
was applied to measure anxiety and depression; a cutoff
score of ≥8 was used for each subscale.29 The SF-36 was
used to evaluate the quality of life. Two summary scores,
physical and mental health, were calculated with adjust-
ment for the Portuguese population.30
Statistical analysis
Descriptive statistics were used for group characterization
and non-parametric tests (ie, chi-square test, Fisher’s exact
test, and Mann–Whitney test) were applied for group
comparisons. Simple and multiple logistic regression ana-
lyses were used to explore associations between the pre-
sence of sleep disturbances and subtypes of pain. The
backward wald method was used for variable selection,
with p>0.100 criterion for variable removal.
The threshold for statistical significance for group com-
parisons and for logistic regressions was p<0.05. The sta-
tistical analysis was conducted using the Statistical Package
for the Social Sciences version 25.0 (SPSS, USA).
Results
Characteristics of the sample
Of the 229 PD patients examined, 122 (53%) were men,
mean age was 69 years (sd=11), mean age at disease
onset was 60 years (sd=12), and mean duration of the
disease was 9 years (sd=6). Ninety-six (42%) were taking
dopamine agonist (ie, 91 ropinirole, 2 pramipexole, 3
piribedil) and the mean levodopa equivalent dose was
900 mg/day (sd=542). The mean ropinirole dose was 10
(sd=5). Mean scores in motor scales were: 32 (sd=11) in
UPDRSS-III off and 22 (sd=9) in on; 2.7 (sd=0.7) in
H&Y off and 2.3 (sd=0.5) in on. One hundred and
thirty-one (57%) had motor fluctuations. Mean in the
functional independence scale S&E were 75 (sd=17) in
off and 87 (sd=11) in on. At the time of the assessment,
162 patients (71%) reported pain. Of those with pain, 99
(61%) had musculoskeletal pain, 43 (27%) had dystonia-
related pain, 38 (24%) had central parkinsonian pain, and
19 (12%) had radicular or neuropathic pain. No patient
reported akathitic discomfort. The frequencies of HADS
≥8 on anxiety and depression subscales were, respec-
tively, 102 (45%) and 111 (49%). Mean SF-36 summary
scores for physical and mental health were, respectively,
40 (sd=11) and 46 (sd=12).
Characterization of sleep disturbances
Mean PDSS-2 total score was 15 (sd=10). One hundred
and fifty-four (67%) patients scored PDSS-2<18 and 75
patients (33%) scored ≥18. Table 1 shows the demographic
and clinical features of these patients. Patients with sleep
disturbances (PDSS-2≥18) had more severe motor symp-
toms (UPDRS in off and on and H&Y in off), more motor
fluctuations, lower functional independence (S&E in off
and on), and were taking higher doses of antiparkinsonian
medication (p<0.05). Patients with PDSS-2≥18 reported
more frequent pain and greater pain intensity were more
Dovepress Vila-Chã et al
Journal of Pain Research 2019:12 submit your manuscript | www.dovepress.com
DovePress
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Table 1 Demographic, clinical, and therapeutic characteristics of PD patients according to PDSS-2 total score
PDSS-2 p
<18 (n=154) ≥18 (n=75)
Sex, men 87 (57%) 35 (47%) 0.162
Age (years) 69 (63–77) 71 (63–75) 0.830
Age at disease onset (years) 60 (53–70) 61 (53–67) 0.626
PD disease duration (years) 7 (4–11) 8 (5–14) 0.214
UPDRS III Off 29 (22–36) 37 (29–45) <0.001
On 19 (14–26) 25 (19–32) <0.001
H&Y Off 2.5 (2–3) 3 (2–4) 0.006
On 2 (2–2.5) 2.5 (2–2.5) 0.051
Motor fluctuations 78 (51%) 53 (71%) 0.004
S&E Off 80 (70–90) 70 (50–80) <0.001
On 90 (80–90) 80 (70–90) <0.001
Dopamine agonists 64 (44%) 29 (35%) 0.486
LED (mg/day) 700 (460–1040) 1,027 (600–1410) 0.001
Hypnotic medication 0.439
No medication 56 (36%) 26 (35%)
BDZ 48 (31%) 22 (29%)
BDZ agonist 2 (1%) 0 (0%)
Tricyclic and tetracyclic
antidepressants
14 (9%) 5 (7%)
Antipsychotic 5 (3%) 8 (11%)
Anticonvulsant 3 (2%) 1 (1%)
Other antidepressants 11 (7%) 7 (9%)
Combination of hypnotic medications 15 (10%) 6 (8%)
Pain 101 (66%) 61 (81%) 0.014
BPI 23 (21–31) 34 (24–43) <0.001
HADS Anxiety ≥8 55 (36%) 47 (63%) <0.001
Depression ≥8 59 (38%) 52 (69%) <0.001
SF-36 Physical health 42 (33–51) 32 (28–43) <0.001
Mental health 50 (41–57) 43 (34–49) <0.001
Notes: UPDRS-III on, H&Y on, and S&E on were not applied to untreated patients. Data are presented as frequencies (%) and as medians (25th–75th percentiles). Chi-
square test (or Fisher’s exact when appropriate) and Mann–Whitney test were used for group comparisons.
Abbreviations: UPDRS, Unified Parkinson's Disease Rating Scale; H&Y, Hoehn & Yahr scale; S&E, Schwab and England Independence Scale; LED, Levodopa Equivalent Dose;
BZD, Benzodiazepines; BPI, Brief Pain Inventory; HADS, Hospital Anxiety and Depression Scale; SF-36, Short Form (36 itens) Health Survey.
Vila-Chã et al Dovepress
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anxious and depressed (HADS), and had poorer quality of
life (SF-36 physical and mental health summary scores)
than patients with PDSS-2<18. These two groups did not
differ (p>0.05) regarding sex, age, age at disease onset,
disease duration, and use of dopamine agonists (including
type and dose) and hypnotic medication.
Sleep disturbances and subtypes of pain
The frequency of sleep disturbances was 20% for patients
without pain and 38% for patients with pain (p=0.014). In
comparison with patients without pain, the frequency of
sleep disturbances was significantly higher for patients
with central parkinsonian pain (53%, p=0.001), but not
for musculoskeletal pain (32%, p=0.107), dystonia-related
pain (37%, p=0.061), or radicular/neuropathic pain (26%,
p=0.755).
Among patients with pain, a simple logistic regression
revealed that the odds of having sleep disturbances were
higher among patients with central parkinsonian pain
(odds=2.25, 95% CI: 1.08–4.71; p=0.031). No significant
association was found with musculoskeletal pain, dysto-
nia-related pain, or radicular/neuropathic pain (Table 2).
When adjusted for severity of motor symptoms in off
(H&Y), presence of motor fluctuations, pain intensity
(BPI), anxiety, and depression (HADS), the odds of having
sleep disturbances remained higher in patients with central
parkinsonian pain (adjusted odds=2.46, 95% CI: 1.06–
5.74; p=0.037).
Discussion
In a series of 229 PD patients, the prevalence of sleep
disturbances was 33% and of pain was 71%. The fre-
quency of sleep disturbances is similar to another study
that used PDSS-2≥18.31 Although it is lower than other
published series, with prevalence estimates of sleep dis-
turbances ranging between 40% and 90%.4,32 This wide
variation is likely due to methodological differences (ie,
assessment instruments and applied cutoffs). The preva-
lence of pain in our series is consistent with other cohorts
of PD.8,9,33
In accordance with a recent study,15 PD patients with
sleep disturbances had more severe motor symptoms, more
anxiety and depression symptoms, lower functional inde-
pendence, and poorer quality of life. As previously identi-
fied in other cohorts,13,32 the intensity of pain among PD
patients with sleep disturbances was significantly higher
than in patients without clinically relevant sleep
disturbances.
Presence of motor fluctuations was also more frequent
among patients with sleep disturbances. Previous studies
have demonstrated that motor fluctuations are more com-
mon in PD patients who report pain.34–36 This pattern of
findings raises the possibility that motor fluctuations may
have a modulating effect on the relationship between pain
and sleep.
The study results also demonstrate that the association
between quality of sleep and pain in PD depends on pain
subtype. Similar to other cohorts,9,16,33,37 musculoskeletal
and dystonia-related pain were the most common subtypes
of pain. Although only central parkinsonian pain was sig-
nificantly related to an increased risk of sleep disturbances,
both in comparison to patients without pain and to patients
with other pain subtypes. Patients with musculoskeletal
pain or dystonia-related pain tended to have more sleep
disturbances than patients without pain. However, among
patients with pain, these pain subtypes were not related to
an increased risk of sleep disturbances. The relationship
between central parkinsonian pain and sleep disturbances
was not statistically dependent on disease severity, pre-
sence of motor fluctuations, pain intensity, or mood
symptoms.
Ford’s classification of pain is specific for patients with
PD and is based on the likely etiology of pain.17 Even
though it has been widely accepted,38 Ford’s criteria are
not universally used and have not been thoroughly vali-
dated. This limits the comparison with other cohorts.
In the general population, several studies have shown
that sleep deprivation leads to changes in pain processing
with increased sensitivity to pain and a hyperalgesic
effect,39 whereas longer nocturnal sleeping time may
reduce pain perception.40 Persistent pain is also known
to have a great impact on sleep and is one of the most
frequent causes of sleep disturbances in older adults.41,42
In a recent study, Krause et al43 provided a central brain
framework for the underlying impact of sleep loss in
Table 2 Odds of patients with pain (n=162) having PDSS-2 total
score ≥18 according to pain subtypes
Subtype of pain Odds P Adjusted odds* p
Central parkinsonian 2.25 0.031 2.46 0.037
Musculoskeletal 0.56 0.080 - -
Neuropathic 0.56 0.283 - -
Dystonic 0.974 0.994 - -
Notes: *The odds of having PDSS-2 total score ≥18 for each subtype of pain
adjusted for H&Yoff, motor fluctuations, BPI score, HADS – anxiety ≥8, and HADS
– depression ≥8, with backward – wald selection method.
Dovepress Vila-Chã et al
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pain. They demonstrated that acute sleep-deprivation
amplifies pain reactivity within human primary somato-
sensory cortex, but blunts pain-reactivity in higher order
valuation and decision-making regions of the striatum
and insula cortex.
Both pain and sleep disturbances are known to involve
brainstem structures and changes in neurotransmitter sys-
tems, namely dopamine.44–46 The existing clinical evi-
dence suggests an important role of the dopaminergic
deficit in central parkinsonian pain47 and it has been well
demonstrated that dopamine contributes to the promotion
and maintenance of arousal states and regulation of sleep
and wakefulness.11,48 The ascending reticular activating
system, including parts of raphe nuclei which is a crucial
sleep modulation center, has many dopaminergic receptors
and pain induced alterations in dopaminergic system, that
may deregulate raphe cells and contribute to long-term
sleep loss.44,45 Changes in the striatum and dopamine
depletion are hallmarks of PD. However, the pathophysio-
logical relationship between sleep and pain in PD is not
yet understood.
The recruitment of participants to the study was con-
secutive. However, a significant number of subjects were
unable to complete parts of the protocol due to cognitive
impairment. The exclusion of participants with missing
data set may have reduced the representativeness of the
sample. The a priori exclusion of patients under advanced
therapies for PD, namely deep brain stimulation, also
reduces the representativeness of the sample, especially
in the advanced stages of the disease. Another limitation
of the study is the identification of sleep disturbances only
by a self-report screening questionnaire, which is vulner-
able to misrepresentation of the actual pattern and quality
of sleep. As this study did not explore the characteristics
of sleep disturbance, future studies ought to include poly-
somnographic recordings for further characterization and
the level of arousal during the day should be taken into
account. One major strength of this study is the diagnosis
of PD and the clinical evaluation by movement disorders
specialists, which reduces the risk of misdiagnosis.
In summary, sleep disturbances and pain are prevalent
non-motor symptoms in PD. Poor quality of sleep is asso-
ciated with more pain and more severe motor symptoms,
anxiety, depression, and poorer quality of life. The study
results revealed that the association between pain and
sleep disturbances in PD appears to be dependent on the
subtype of pain.
Conclusion
Patients with central parkinsonian pain are particularly prone
to experience sleep disturbances. This relationship ought to be
explored in future neurophysiological studies. A better under-
standing of the relationship between sleep disturbances and
central parkinsonian pain may contribute to the development
of new care strategies in PD patients.
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